Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis

Guochun Zhou; Chiawei W. Tsai; Jun O. Liu

doi:10.1021/jm0341103

Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis

Guochun Zhou, Chiawei W. Tsai, Jun O. Liu

School of Medicine

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Fumagillin and ovalicin constitute a family of structurally related natural products that possess antiangiogenic activity. We report the synthesis of a new fumagillin analogue, fumagalone, in which the spiroepoxide group is replaced with an aldehyde. Fumagalone inhibits type 2 methionine aminopeptidase (MetAP2) with IC₅₀ = 8 μM and endothelial cell proliferation with IC₅₀ = 52 nM. With dialysis and competition assays, it was unambiguously demonstrated that binding of fumagalone to MetAP2 is reversible.

Original language	English (US)
Pages (from-to)	3452-3454
Number of pages	3
Journal	Journal of medicinal chemistry
Volume	46
Issue number	16
DOIs	https://doi.org/10.1021/jm0341103
State	Published - Jul 31 2003

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1021/jm0341103

Cite this

@article{c1245d8428414d63a40ae4540724cb81,

title = "Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis",

abstract = "Fumagillin and ovalicin constitute a family of structurally related natural products that possess antiangiogenic activity. We report the synthesis of a new fumagillin analogue, fumagalone, in which the spiroepoxide group is replaced with an aldehyde. Fumagalone inhibits type 2 methionine aminopeptidase (MetAP2) with IC50 = 8 μM and endothelial cell proliferation with IC50 = 52 nM. With dialysis and competition assays, it was unambiguously demonstrated that binding of fumagalone to MetAP2 is reversible.",

author = "Guochun Zhou and Tsai, {Chiawei W.} and Liu, {Jun O.}",

year = "2003",

month = jul,

day = "31",

doi = "10.1021/jm0341103",

language = "English (US)",

volume = "46",

pages = "3452--3454",

journal = "Journal of medicinal chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "16",

}

TY - JOUR

T1 - Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis

AU - Zhou, Guochun

AU - Tsai, Chiawei W.

AU - Liu, Jun O.

PY - 2003/7/31

Y1 - 2003/7/31

N2 - Fumagillin and ovalicin constitute a family of structurally related natural products that possess antiangiogenic activity. We report the synthesis of a new fumagillin analogue, fumagalone, in which the spiroepoxide group is replaced with an aldehyde. Fumagalone inhibits type 2 methionine aminopeptidase (MetAP2) with IC50 = 8 μM and endothelial cell proliferation with IC50 = 52 nM. With dialysis and competition assays, it was unambiguously demonstrated that binding of fumagalone to MetAP2 is reversible.

AB - Fumagillin and ovalicin constitute a family of structurally related natural products that possess antiangiogenic activity. We report the synthesis of a new fumagillin analogue, fumagalone, in which the spiroepoxide group is replaced with an aldehyde. Fumagalone inhibits type 2 methionine aminopeptidase (MetAP2) with IC50 = 8 μM and endothelial cell proliferation with IC50 = 52 nM. With dialysis and competition assays, it was unambiguously demonstrated that binding of fumagalone to MetAP2 is reversible.

UR - http://www.scopus.com/inward/record.url?scp=0042343842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042343842&partnerID=8YFLogxK

U2 - 10.1021/jm0341103

DO - 10.1021/jm0341103

M3 - Article

C2 - 12877582

AN - SCOPUS:0042343842

SN - 0022-2623

VL - 46

SP - 3452

EP - 3454

JO - Journal of medicinal chemistry

JF - Journal of medicinal chemistry

IS - 16

ER -

Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this